Company intelligence / Profile preview
Mediolanum Farmaceutici
Milan, Lombardy, Italybancamediolanum.it ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Mediolanum Farmaceutici has a diversified pipeline with several clinical-stage assets. Notable programs include GX‑301 (a telomerase peptide cancer vaccine in Phase 2 for prostate cancer), PP‑001 (a small molecule in early clinical development for uveitis), ACT‑017 (a humanized Fab in preclinical development for acute ischemic stroke), and several immuno-oncology antibodies from the ElsaLys Biotech acquisition. The company also markets approved drugs such as dermatan sulfate for thrombosis[3][5][7].
- Therapeutic areas
- OncologyMetabolic DisordersEndocrinologyPulmonologyImmunologyRheumatologyCardiovascularOphthalmology
- Modalities
- Monoclonal antibodySmall moleculeAntibodyTherapeutic vaccineBispecific antibodyHumanized monoclonal antibody fragmentSmall molecule/polysaccharide
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Novartis OncologyPanoptesActicorApeptico
Beyond the preview
Go deeper on Mediolanum Farmaceutici.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mediolanum Farmaceutici.